LetSync: Pilot Test of Mobile Health (mHealth) Intervention

HIV/AIDS Clinical Trial

Official title:

Pilot-test of an mHealth Black Men Who Have Sex With Men (MSM) in Couples Intervention (LetSync v1.0, v2.0)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04951544
• Other study ID #: 5R01MH118967-03
• Secondary ID: 5R01MH118967-03
• Status: Recruiting
• Phase: N/A
• Start date: March 15, 2023
• Est. completion date: February 2024

Study information

• Verified date: February 2023
• Source: University of California, San Francisco
• Contact: Judy Y Tan, Ph.D.
• Phone: 415-502-1000
• Email: judy.tan[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Pilot Test (AKA Study B) will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. In the ensuing 2 months, the investigators will make refinements based on participants' data to produce LetSync v2.0. Then, participants in the waitlist-control arm will receive LetSync v2.0, use it for 6 months, and provide acceptability and feasibility data. The intervention arm will continue using LetSync v1.0, for a total of 14 months. Based on acceptability and feasibility data from waitlist control arm participants between T3 and T4, the investigators will develop LetSync v3.0, which will be used for efficacy testing in a full RCT trial in the future.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: February 2024
• Est. primary completion date: February 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Individuals are eligible if they:

• Self-identify as racial/ethnic minority
• Self-identify as a cisgender man
• Are HIV-Positive themselves, or are the partner of someone who is living with HIV
• Are age 18 or older
• Have a primary relationship partner, defined as someone to whom the participant is committed above anyone else for three or more months
• Uses and owns a personal smartphone
• Willing and able to provide informed consent

Partners are eligible if they:

• Self-identify as a cisgender man
• Are age 18 or older
• Have a primary relationship partner that is the referring participant
• Uses and owns a personal smartphone
• Willing and able to provide informed consent Exclusion Criteria:

Those who:

• Report fear of intimate partner violence (IPV) resulting from participation
• Are unwilling or unable to disclose HIV status to primary partner
• Present evidence of severe cognitive impairment that would prevent comprehension of study procedures assessed during informed consent

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• HIV/AIDS

Intervention

Other:
• LetSync v1.0
Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
• LetSync v2.0
LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.

Locations

Country	Name	City	State
United States	University of California San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Levels of Antiretroviral (ARV) concentration in dried blood spot (DBS) samples	The investigators will use the UNC Pharmacology Lab to analyze ARV levels in dried blood spot (DBS) samples as an objective measure of drug adherence and exposure for HIV-infected participants. The investigators will mail participants a DBS sample collection kit with necessary supplies, detailed instructions via online demonstration video, and a prepaid return envelope. DBS samples will be collected and analyzed between baseline (T0) and 8 months (T4).; ARV levels will be measured as nanograms per milligram (ng/mg) of DBS will be log-transformed for data analysis. Changes since Baseline of ARV levels will be measured.	8 months
Primary	Self-reported measure of care engagement	Self-reported care engagement will be measured with the 10-item Index of Engagement in HIV Care rated on a Likert-type scale ranging from 1 to 5, 'Strongly disagree' to 'Strongly agree'. This will be included in questionnaires administered to participants between baseline (T0) and 8 months (T4).; A mean Index score will be calculated (the sum of all items without missing responses divided by that number of items), with a higher score representing better care engagement and lower score representing worse care engagement. Changes since Baseline of the mean Index score will be measured.	8 months
Primary	Self-reported measure I of antiretroviral therapy (ART) adherence	Self-reported antiretroviral therapy (ART) adherence will be measured using an aggregated or composite score derived from the following items. Frequency of missed doses will be represented by summing the following two items: how many doses were missed over the last 30 days, and how many doses missed over the past three months for at least four days in a row.	8 months
Primary	Self-reported measure II of antiretroviral therapy (ART) adherence	Self-reported antiretroviral therapy (ART) adherence will be measured using an aggregated or composite score derived from the following items on a Likert-type scale of 1 to 5, 'Strongly disagree' to 'Strongly agree': Self-rated ability of taking medications the way they should, how often they took medications the way they should.; For self-rated ability of taking medications and frequency of taking them, a mean score will be calculated (the sum of all items without missing responses divided by that number of items). A higher score represents excellent ability of taking medications and a lower score represents poor ability of taking medications. Changes in Baseline for the mean Index score will be measured.	8 months
Primary	Presence of Antiretroviral (ARV) medication in urine sample	The investigators will use self-collected urine samples as another objective measure of drug adherence for participants living with HIV. The investigators will mail participants a urine sample collection kit with necessary supplies and detailed instructions via online demonstration video. Participants will self-collect and administer the urine sample and send a photo of the results to study staff. Urine test results will be collected between baseline (T0) and 8 months (T4).	8 months
Secondary	Feasibility or usability of LetSync app v1.0 (how easy or convenient is v1.0 to use)	Between baseline (T0) and 8 months (T4), the investigators will collect feasibility-related data via the app using a validated 10-item Feasibility instrument. The items are on a five-point Likert scale ranging from 'Strongly disagree' to 'Strongly agree'. A mean Feasibility score will be calculated (the sum of all items without missing responses divided by that number of items). A higher score indicates high feasibility, whereas a lower score indicates low feasibility.; Feasibility data collected only between baseline (T1) and 6 months (T2) will be used to develop LetSync app v2.0 for the Waitlist-control arm. Investigators will continue collecting acceptability data on LetSync app v1.0 from the Intervention arm.	8 months
Secondary	Acceptability of or Satisfaction in using LetSync app v1.0	Between baseline (T0) and 14 months (T5), the investigators will collect acceptability data via the app using a validated 5-item Feasibility instrument. The items are on a five-point Likert scale (1 to 5) ranging from 'Strongly disagree' to 'Strongly agree'. A mean Acceptability score will be calculated (the sum of all items without missing responses divided by that number of items). A higher score indicates high acceptability, whereas a lower score indicates low feasibility.; Acceptability data collected only between baseline (T1) and 6 months (T2) will be used to develop LetSync app v2.0 for the Waitlist-control arm. Investigators will continue collecting acceptability data on LetSync app v1.0 from the Intervention arm.	8 months
Secondary	Self-reported care engagement	The investigators will collect data on participants' self-reported care engagement; this will be comprised of scheduled, cancelled, rescheduled, and attended visits to their HIV and/or primary care provider within the last three to six months. Data will be collected via questionnaires administered to participants between baseline (T0) and 8 months (T4). The investigators will measure changes from Baseline for each item of interest.	8 months